• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1259969 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
# S2 O, u( \. \( b2 N" S: QNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
2 v7 G0 e, H8 U2 z8 c6 L: t# x+ Author Affiliations
8 d  l6 L% t6 J/ L0 c/ |# @' ~/ B, {; \7 p& J" a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
0 L1 G; }/ A# V; t2 _( i$ x; x2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan   @! ^7 w0 `! {: t: m3 @% f
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; _* Y+ r$ Y; _) f  Y7 p  S4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + `, b6 d. D! C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
9 X% U2 M; t- l7 ~8 i6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 K5 k/ a4 j7 t( ]7Kinki University School of Medicine, Osaka 589-8511, Japan . ?5 B3 I, W. E% _" ]
8Izumi Municipal Hospital, Osaka 594-0071, Japan ( z7 U4 x/ v6 e8 q
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan   M1 I2 |- {( l# c& Y2 a* M
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 g/ u2 }1 D  L  UAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
) ~" z% U- `7 o5 P: H7 _2 N& B( @  s$ `* c2 [6 B
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
% U+ H5 S/ @3 m5 v( b; b
8 V! U4 i! y* E# k  zAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato ( R  O- L5 G0 `* l
( R/ |# H+ @. ?, O
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  , W  z0 S/ _0 C+ I9 ~* R
$ T: Z/ J5 `0 H5 m! x
Published online on: Thursday, December 1, 2011 6 U/ Y+ P0 _7 U6 q7 Y/ k, B7 k3 e

, S" x' n( c* UDoi: 10.3892/ol.2011.507
& k5 m3 S. b: a$ L$ Q" s
: ?0 J5 V5 Q& }( k$ bPages: 405-410
# C& q" O9 G( A: M- p6 R& W( x7 E" j1 W, O; }9 T
Abstract:- q6 y" n; V  G8 I; j* e
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
" m8 k7 k* C5 P- q% a. V9 t2 b
, z" S6 P+ D6 H; X9 U- l: }& w$ T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population4 E. z* ~+ P' }1 m% g8 b! D
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 / }9 g$ X9 s& h' E! V  Y2 m
+ Author Affiliations) m( f2 m9 B+ T  E$ D
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu * L# R+ R0 t/ h7 d
2Department of Thoracic Surgery, Kyoto University, Kyoto
# P- O6 v1 T7 I, a% n% B* K3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan + }# D; A0 K( }9 Q# c4 Y- Q; |! P
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
0 j, m+ D2 A9 [4 C: a! VReceived September 3, 2010.
; I: f( X! h- K7 |Revision received November 11, 2010. ' k* G/ A8 Q' c2 f: T! n0 j5 U
Accepted November 17, 2010.
8 @! G0 m, A( U( {( g# MAbstract
) i" @9 {* U: i! m3 b( DBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 9 |3 v! F6 F! U8 p
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. / q  l/ e& i, o: k1 Y5 C: e
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
6 |( \+ R8 k. O8 f% I/ GConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 4 H  n* W* h6 b) c
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。& _- V5 _' x& i, f; ^
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?5 w' z1 P7 Q: u3 W1 x  x
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
2 k3 k& w+ x. c. ]7 \http://clinicaltrials.gov/ct2/show/NCT015235872 c- i' r% f; T  t# n
( D7 C/ ?6 @4 M1 L( R, ~: x7 S
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC+ k- ^4 O9 S& N/ s  P4 D
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
$ m8 l& l3 d# ?; C" I. k8 e& \+ E2 ^  D0 k! g* a
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
/ r$ j" Q4 c: A至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
" w% y( g' s2 d5 @1 r4 g. N
没有副作用是第一追求,效果显著是第二追求。% z( H9 @1 U% x7 F4 r* N# j
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表